WO2001085770A2 - Sentinel virus ii - Google Patents
Sentinel virus ii Download PDFInfo
- Publication number
- WO2001085770A2 WO2001085770A2 PCT/EP2001/005029 EP0105029W WO0185770A2 WO 2001085770 A2 WO2001085770 A2 WO 2001085770A2 EP 0105029 W EP0105029 W EP 0105029W WO 0185770 A2 WO0185770 A2 WO 0185770A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- svii
- protein
- virus
- polynucleotide
- isolated
- Prior art date
Links
- 241000790264 Sentinel virus II Species 0.000 title abstract description 231
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 110
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 110
- 239000002157 polynucleotide Substances 0.000 claims abstract description 110
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 103
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 98
- 241000700605 Viruses Species 0.000 claims abstract description 54
- 239000013604 expression vector Substances 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 239000000523 sample Substances 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 48
- 125000003729 nucleotide group Chemical group 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 21
- 238000009396 hybridization Methods 0.000 claims description 17
- 229960005486 vaccine Drugs 0.000 claims description 15
- 230000000692 anti-sense effect Effects 0.000 claims description 14
- 230000000295 complement effect Effects 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 11
- 238000013518 transcription Methods 0.000 claims description 10
- 230000035897 transcription Effects 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 20
- 108010067390 Viral Proteins Proteins 0.000 abstract description 10
- 238000003259 recombinant expression Methods 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 48
- 208000006454 hepatitis Diseases 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 43
- 238000001514 detection method Methods 0.000 description 40
- 108090000765 processed proteins & peptides Proteins 0.000 description 35
- 102000004196 processed proteins & peptides Human genes 0.000 description 34
- 231100000283 hepatitis Toxicity 0.000 description 33
- 229920001184 polypeptide Polymers 0.000 description 30
- 230000003321 amplification Effects 0.000 description 25
- 238000003199 nucleic acid amplification method Methods 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 24
- 238000003556 assay Methods 0.000 description 21
- 238000003752 polymerase chain reaction Methods 0.000 description 21
- 230000003612 virological effect Effects 0.000 description 19
- 239000002245 particle Substances 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 108700026244 Open Reading Frames Proteins 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 241000711549 Hepacivirus C Species 0.000 description 12
- 241000700721 Hepatitis B virus Species 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 108091093088 Amplicon Proteins 0.000 description 10
- 230000002163 immunogen Effects 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 238000005119 centrifugation Methods 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 238000003018 immunoassay Methods 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 206010008909 Chronic Hepatitis Diseases 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 108020005202 Viral DNA Proteins 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 231100000354 acute hepatitis Toxicity 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 208000037262 Hepatitis delta Diseases 0.000 description 4
- 241000724709 Hepatitis delta virus Species 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 229940023143 protein vaccine Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 206010019799 Hepatitis viral Diseases 0.000 description 3
- 208000037581 Persistent Infection Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000007857 nested PCR Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 201000001862 viral hepatitis Diseases 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 101000666833 Autographa californica nuclear polyhedrosis virus Uncharacterized 20.8 kDa protein in FGF-VUBI intergenic region Proteins 0.000 description 2
- 101000977027 Azospirillum brasilense Uncharacterized protein in nodG 5'region Proteins 0.000 description 2
- 101000962005 Bacillus thuringiensis Uncharacterized 23.6 kDa protein Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 101000785191 Drosophila melanogaster Uncharacterized 50 kDa protein in type I retrotransposable element R1DM Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000747704 Enterobacteria phage N4 Uncharacterized protein Gp1 Proteins 0.000 description 2
- 101000861206 Enterococcus faecalis (strain ATCC 700802 / V583) Uncharacterized protein EF_A0048 Proteins 0.000 description 2
- 101000769180 Escherichia coli Uncharacterized 11.1 kDa protein Proteins 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 241000531123 GB virus C Species 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000724675 Hepatitis E virus Species 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101000976301 Leptospira interrogans Uncharacterized 35 kDa protein in sph 3'region Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101000658690 Neisseria meningitidis serogroup B Transposase for insertion sequence element IS1106 Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000701945 Parvoviridae Species 0.000 description 2
- 101000748660 Pseudomonas savastanoi Uncharacterized 21 kDa protein in iaaL 5'region Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 101000584469 Rice tungro bacilliform virus (isolate Philippines) Protein P1 Proteins 0.000 description 2
- 241000959822 SEN virus Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101000818096 Spirochaeta aurantia Uncharacterized 15.5 kDa protein in trpE 3'region Proteins 0.000 description 2
- 101000766081 Streptomyces ambofaciens Uncharacterized HTH-type transcriptional regulator in unstable DNA locus Proteins 0.000 description 2
- 101000804403 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HIT-like protein Synpcc7942_1390 Proteins 0.000 description 2
- 101000750910 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HTH-type transcriptional regulator Synpcc7942_2319 Proteins 0.000 description 2
- 101000644897 Synechococcus sp. (strain ATCC 27264 / PCC 7002 / PR-6) Uncharacterized protein SYNPCC7002_B0001 Proteins 0.000 description 2
- 101000916336 Xenopus laevis Transposon TX1 uncharacterized 82 kDa protein Proteins 0.000 description 2
- 101001000760 Zea mays Putative Pol polyprotein from transposon element Bs1 Proteins 0.000 description 2
- 101000678262 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 65 kDa protein Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- -1 viral Substances 0.000 description 2
- 210000000605 viral structure Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 206010065051 Acute hepatitis C Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 108010054278 Lac Repressors Proteins 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101500017934 Sus scrofa Saposin-B Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000037621 acute hepatitis C virus infection Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 1
- 229940009859 aluminum phosphate Drugs 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000001317 epifluorescence microscopy Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000003494 hepatotrophic effect Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical class NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000005582 sexual transmission Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012610 weak anion exchange resin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the invention relates to the field of viruses, and particularly to hepatitis viruses.
- hepatitis refers to an inflammation of the liver.
- a variety of different chemical, viral, and biological agents will induce hepatitis.
- hepatitis more commonly refers to an inflammation of the liver caused by a viral infection, particularly a hepatotrophic viral infection.
- Viral hepatitis can be divided into two gross categories: acute and chronic.
- Acute viral hepatitis is characterized by jaundice, malaise, nausea, and elevated blood liver enzymes. Although most cases of viral hepatitis resolve spontaneously, a portion of acute hepatitis victims (generally less than about 10%) develop fulminant necrotizing hepatitis, a disorder with very high morbidity and mortality. Interestingly, many cases of acute hepatitis are so mild as to pass unnoticed or be dismissed as
- Chronic hepatitis gives rise to a much more significant public health problem, and is the most common reason for liver transplant in the United States. Chronic hepatitis is characterized by exacerbations or "flare ups" with symptoms resembling acute hepatitis, as well as portal hypertension and cirrhosis (scarring of the liver) which leads to liver failure. Because acute hepatitis infections can go unnoticed, many chronic hepatitis patients are not diagnosed until their disease is quite advanced, limiting options for treatment.
- hepatitis viruses There are six different families of viruses referred to as “hepatitis viruses" (A, B, C, D, E and G; F having been found to be artifactual). In developed countries, those hepatitis viruses that can establish chronic infections are generally considered to be the most important viruses from a public health standpoint. Of the hepatitis viruses, hepatitis B virus and hepatitis C virus are the only known hepatitis viruses known to establish chronic infections associated with chronic hepatitis. However, HBN and HCN do not account for all cases of transfusion hepatitis. The terms "cryptogenic hepatitis” and “nonA-G” are used to refer to transfusion hepatitis that cannot be attributed to a known hepatitis virus.
- Hepatitis B previously referred to as "transfusion hepatitis” is transmitted via percutaneous, sexual, and vertical routes.
- the hepatitis B virus a member of the hepadnaviridae family, can give rise to both acute and chronic hepatitis.
- the hepatitis B virus (HBV) has been well characterized, and a variety of screening and diagnostic assays are currently available. Additionally, a recombinant vaccine has been created which is currently required for most school age children in the United States.
- Hepatitis C previously known as "non-A, non-B hepatitis” is transmitted primarily via the percutaneous route, although, like HBV, sexual and vertical transmission also occur. Only a minority of acute hepatitis C virus (HCV) infections are clinically apparent, which is problematic because this virus establishes chronic infections at a very high rate. This combination makes chronic HCV infection the leading reason for liver transplant in the United States.
- HCV acute hepatitis C virus
- TTV hepatitis-associated virus
- RDA representation difference analysis
- TTV has been proposed as the prototypic human member of a family of viruses known as the circinoviridae for their circular, single-stranded DNA genomes (Mushahwar et al., 1999, Proc. Natl. Acad. Set USA, 96(6):3177-3182).
- SEN-V The virus, termed SEN-V, was later found to be highly prevalent in the healthy population and not limited to blood samples from hepatitis patients and is unlikely a hepatitis virus. Neither the polynucleotide sequence nor methods for isolation of SEN-V have been disclosed.
- compositions and methods for detection of non-A/non-G hepatitis as well as compositions and methods for prevention of non-A/non-G hepatitis infections and compositions and methods for treatment of non-A/non-G hepatitis infections.
- compositions comprising isolated SVII virus.
- isolated SVII viruses include isolated viruses comprising the polynucleotide sequence of FIG. 1.
- Isolated polynucleotides including an isolated polynucleotide selectively hybridizable with the nucleotide sequence of FIG. 1 and complements thereof, an isolated polynucleotide encoding an isolated SVII protein or fragment thereof and complements thereof.
- the isolated polynucleotide may be an antisense polynucleotide.
- compositions comprising an isolated SVII protein or fragment thereof.
- Vaccine compositions comprising an isolated SVII protein or fragment thereof.
- the vaccine compositions may include a pharmaceutically acceptable excipient and/or an adjuvant.
- Expression vectors comprising an isolated polynucleotide encoding a SVII protein or fragment thereof.
- Expression vectors comprising an isolated polynucleotide, wherein transcription of said isolated polynucleotide results in the production of an SNII antisense polynucleotide.
- SVII virus or a protein thereof comprising contacting a sample with an antibody which binds to SVII virus or a protein thereof; and detecting complexes of said antibody and SVII virus or protein thereof.
- Methods for detecting SVII virus comprising contacting a sample with a probe polynucleotide which selectively hybridizes to a SVII polynucleotide and detecting hybridization of said probe with a SVII polynucleotide.
- Methods for detecting SVII virus comprising contacting a sample with a first primer polynucleotide that selectively hybridizes with a SVII polynucleotide and a second primer polynucleotide that hybridizes with a complement of the SVII polynucleotide, performing primer extension DNA synthesis, and detecting the product of the synthesis.
- FIG. 1 shows nucleotide sequence and conceptual translations of open reading frames from a Sentinel Virus II (SVII) clone (standard single letter coding is employed; k, m, r, s, y and w indicate T/G, A/C, G/A, G/C, T/C and A/T, respectively).
- SVII Sentinel Virus II
- k, m, r, s, y and w indicate T/G, A/C, G/A, G/C, T/C and A/T, respectively.
- the strand designated "positive” is labeled "+”, and its inverse complement is labeled "-”. Numbering refers to the + strand nucleotide sequence.
- Open reading frames PI, Ml and M2 are also shown. The - strand and the Ml and M2 reading frames are read right to left.
- Sentinel a new hepatitis virus
- Virus II that is associated with cryptogenic, nonA-G hepatitis.
- the prototypic virus comprises a DNA genome of at least about 371 bases. Genomic sequence from the prototypic virus is shown in FIG. 1. Accordingly, the invention provides isolated SVII. In one aspect, the invention provides isolated polynucleotides comprising the
- SVII viral genome and fragments thereof The polynucleotides may be DNA or RNA. Also provided are isolated nucleotide probes or primers for use in detecting SVII infections and/or SVII virus itself. The probes and/or primers may also be used in methods for identification and isolation of new variants of SVII.
- a further aspect of the invention provides isolated SVII viral proteins and/or fragments thereof, as well as fusion proteins comprising a SVII viral protein or fragment thereof fused with a heterologous (non-SVII) protein. Also included are mosaic polypeptides that comprise at least two SVII epitopes.
- mosaic polypeptides of the invention comprising two epitopes from the same SVII protein
- the intervening amino acids- between the epitopes are substantially deleted or substituted with a heterologous sequence.
- mosaic polypeptides of the invention may comprise two epitopes from different SVII proteins or comprise homologous epitopes from at least two viruses of the SVII family.
- the invention provides recombinant expression constructs, comprising a polynucleotide sequence derived from an open reading frame of an SVII virus operably linked to promoter operable in a prokaryotic or eukaryotic host cell. Also provided are expression vectors and recombinant host cells comprising the expression constructs.
- antibodies specific for epitopes of the SVII family of viruses include monoclonal antibodies and isolated polyclonal antibodies.
- the invention provides assays and kits for conducting assays for detection of SVII infection and/or detection of SVII virus.
- the assays of the invention may be immunoassays utilizing polypeptides or antibodies of the invention or nucleic acid-based assays employing hybridization or amplification technology with one or more polynucleotides of the invention.
- the invention provides vaccines for prevention and/or treatment of SVII infection.
- the vaccines may be protein-based or DNA-based vaccines.
- Protein-based vaccines comprise one or more polypeptides derived from SVII, optionally combined with an adjuvant.
- DNA-based vaccines comprise a isolated polynucleotide encoding a SVII polypeptide or polypeptide fragment operably linked to a promoter active in the subject to be vaccinated (e.g., active in human cells if the subject to be vaccinated is a human).
- Sentinel Virus II and “SVII” refer to a virus, type of virus, or class of virus which is transmissible via percutaneous exposure in humans and is sero logically distinct from hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis
- SVII comprises a genome with a major open reading frame (ORF) with at least about 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%), 99%) or 100% global amino acid sequence homology with the amino acid sequence of FIG. 1 and/or at least about 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,
- a "SVII variant” may have at least about 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%) or 100%) global nucleotide sequence identity with the sequence of FIG.1, encode an ORF with at least about 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
- SVII polypeptide or "SVII protein” is a polypeptide encoded by an ORF of a SVII virus genome. Exemplary SVII polypeptides are shown in the amino acid sequence shown in FIG. 1.
- a SVII polypeptide is at least about 8, 10, 12, 15, 20, 25, 30, 40, or 50 amino acids and may be less than about 250, 200, 150, 134, 125, 110, 100, 90, 80, 70, 60 or 50 amino acids, wherein the upper and lower limits are independently selected except that the upper limit is always greater than the lower limit.
- a "variant SVII polypeptide” is a polypeptide which has at least about 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence homology with the any of the corresponding amino acid sequences of FIG. 1 and/or at least about 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% amino acid sequence identity with the corresponding portion of the any of the amino acid sequences of FIG. 1.
- a variant SVII polypeptide is at least about 8, 10, 12, 15, 20, 25, 30, 40, or 50 amino acids and may be less than about 250, 200, 150, 134, 125, 110, 100, 90, 80, 70, 60 or 50 amino acids, wherein the upper and lower limits are independently selected except that the upper limit is always greater than the lower limit.
- a "SVII polynucleotide” is a polynucleotide with a sequence identical to a polynucleotide or fragment thereof shown in FIG. 1, a complement thereof, or a polynucleotide which encodes a SVII polypeptide or the complement thereof.
- a SVII polynucleotide is at least about 15, 20, 25, 30, 35, 40, 50 or 60 nucleotides and less than about 371, 350, 300, 250, 200, 150, 125, 75, 50, 40, or 30 nucleotides in length, wherein the upper and lower limits are independently selected except that the upper limit is always greater than the lower limit.
- a "complement" to a polynucleotide of interest is a polynucleotide having the inverse complement of the reference polynucleotide, according to Watson-Crick base pairing.
- a complementary polynucleotide is capable of hybridizing under suitable conditions, using
- a "variant SVII polynucleotide” is a polynucleotide which encodes a variant SVII polypeptide or complement thereof or a polynucleotide which is selectively hybridizable to a SVII polynucleotide or complement thereof, but does not fall within the definition of a SVII polynucleotide.
- a variant SVII polynucleotide is not found in any known sequence.
- a variant SVII polynucleotide is at least about 15, 20, 25, 30, 35, 40, 50 or 60 nucleotides and less than about 400, 370, 367, 350, 300, 200, 150, 125, 100, 75 or 50 nucleotides in length, wherein the upper and lower limits are independently selected except that the lower limit is always less than the upper limit.
- amino acid sequence homology and “amino acid sequence identity” refer to the percentage of amino acids that are homologous or the same in comparing the two sequences. This alignment and the percent sequence homology or sequence identity can be determined using software programs known in the art, for example those described in Current Protocols in Molecular Biology (F.M. Ausubel et al., eds., 1987) Supplement 30, section 7.7.18, Table 7.7.1. Preferably, default parameters are used for alignment. For purposes of the present invention, the alignment program is
- Nucleotide sequence identity refers to the percentage of nucleotide residues which are the same in comparing the two sequences. This alignment and the percent sequence identity can be determined using software programs known in the art, for example those described in Current Protocols in Molecular Biology (F.M. Ausubel et al., eds., 1987) Supplement 30, section 7.7.18, Table 7.7.1. Preferably, default parameters are used for alignment.
- a polynucleotide which is "selectively hybridizable" to a SVII polynucleotide sequence is one which (i) hybridizes to a SVII polynucleotide sequence without hybridizing to a known vims polynucleotide sequence or specifically primes amplification of a SVII polynucleotide sequence without priming amplification of a known virus polynucleotide sequence.
- Hybridization of a selectively hybridizable polynucleotide may be accomplished at high stringency, moderate stringency, or low stringency (e.g., allowing for mismatches), as appropriate.
- an "isolated” virus, viral structure (e.g., capsid), polynucleotide or polypeptide is one which has been at least partially purified away from contaminating components found in its normal environment.
- an isolated virus is one which has been at least partially purified away from blood, serum, or tissue proteins.
- the polynucleotide is at least partially purified away from viral proteins and/or other viral components and may additionally be removed from its normal milieu (e.g., nucleotide sequences which normally flank the polynucleotide may be deleted).
- a sequence of interest and regulatory sequences are said to be "operably linked” when they are covalently linked in such a way as to place the expression or transcription of the sequence of interest under the influence or control of the regulatory sequences.
- operably linked relates to the orientation of polynucleotide elements in a functional relationship. Operably linked means that the
- DNA sequences being linked are generally physically contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame. However, since enhancers generally function when separated from the promoter by several kilobases and intronic sequences may be of variable length, some polynucleotide elements may be operably linked but not contiguous.
- two DNA sequences are said to be operably linked if induction of a promoter in the 5' regulatory sequences results in the transcription of the sequence of interest and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the sequence of interest, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein.
- a promoter region would be operably linked to a sequence of interest if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.
- operably linked encompasses operable linkages in which the final protein coding region requires a frameshift or a splice to maintain the proper reading frame through the entire protein coding region (e.g., as seen in certain retroviral systems).
- the term “antibody” means an immunoglobulin molecule or a fragment of an immunoglobulin molecule having the ability to specifically bind to a particular antigen. Antibodies are well known to those of ordinary skill in the science of immunology. As used herein, the term “antibody” means not only intact antibody molecules but also fragments of antibody molecules retaining antigen binding ability. Such fragments are also well known in the art and are regularly employed both in vitro and in vivo.
- the term “antibody” means not only intact immunoglobulin molecules of any isotype (IgA, IgG, IgE, IgD, IgM) but also the well-known active (i.e., antigen-binding) fragments F(ab') 2 , Fab, Fv, scFv, Fd, V H and V L .
- active i.e., antigen-binding fragments
- antibody fragments see, for example “Immunochemistry in Practice” (Johnstone and Thorpe, eds., 1996; Blackwell Science), p. 69.
- the term “antibody” further includes single chain antibodies, CDR-grafted antibodies, diabodies, chimeric antibodies, humanized antibodies, and a Fab expression library.
- the term also includes fusion polypeptides comprising an antibody of the invention and another polypeptide or a portion of a polypeptide (a "fusion partner").
- fusion partners include biological response modifiers, lymphokines, cytokines, and cell surface antigens.
- Antibody activity refers to the ability of an antibody to bind a specific antigen in preference to other potential antigens via the antigen combining site located within a variable region of an immunoglobulin.
- the term “sero logically distinct” describes a polypeptide, protein or virus that can be immunologically identified by specific antibodies as distinct from other species of polypeptides, proteins or viruses by virtue of its antigenic differences from such other species.
- the term “comprising” and its cognates are used in their inclusive sense; that is, equivalent to the term “including” and its corresponding cognates.
- Isolated SVII is preferably prepared from plasma or serum derived from a
- SVII virus may be isolated from serum or plasma using any technique known in the art, including, but not limited to, sedimentation, isopycnic gradient centrifugation, particularly at preparative scale, and immunoisolation.
- SVII viral particles may be isolated using sedimentation techniques (e.g., ultracentrifugation) known in the art. Material containing SVII virus is treated to remove large debris and any cells (e.g., by filtration or medium high speed centrifugation), then ultracentrifuged to sediment SVII virus. Preferably, the material containing SVII is diluted prior to sedimentation of the virus, such as with tris- buffered saline, or tris-buffered saline with EDTA.
- sedimentation techniques e.g., ultracentrifugation
- Material containing SVII virus is treated to remove large debris and any cells (e.g., by filtration or medium high speed centrifugation), then ultracentrifuged to sediment SVII virus.
- the material containing SVII is diluted prior to sedimentation of the virus, such as with tris- buffered saline, or tris-buffered saline with EDTA.
- SVII virus may be sedimented by centrifugation at 200.000 x g for 18 hours (e.g., 200,000 x g in a SW41Ti rotor, with the SVII-containing serum diluted with TEN buffer).
- Isopycnic gradient centrifugation may be performed using any gradient- forming compound known in the art that will form an appropriate gradient, preferably a gradient forming compound that will form a gradient of approximately 1.2 to 1.35 grams per cubic centimeter (g/cm J );sucrose and cesium chloride (CsCl) are preferred gradient forming compounds.
- Plasma or serum containing SVII is layered over sucrose gradient or introduced as a homogenous mixture in CsCl in an appropriate centrifuge tube, then centrifuged to equilibrium.
- Isolated SVII virus may be recovered by collecting the appropriate density fraction of the gradient.
- Immunoisolation techniques utilize SVII-specific antibodies in combination with any appropriate separation media known in the art.
- Preferred separation media include solid plastic substrates (e.g., as for use in panning), chromatographic media
- the SVII antibodies are conjugated to the separation media, which is exposed to a material containing SVII virus. Unbound materials are removed and residual unbound materials are washed away from the immunoseparation substrate, then the bound SVII is eluted, typically by use of an elution buffer with altered pH or high salt concentration.
- isolated SVII virus may be prepared by in vitro culture methods.
- a variety of such methods are known in the art, and normally comprise infecting an appropriate host cell, preferably a liver cell line, with SVII, culturing the infected cells, and collecting SVII viral particles from the culture media or by lysing the host cells. Density gradient separation or immunoisolation techniques may be used to further isolate the virus.
- Isolated SVII polynucleotides may be prepared by any method known in the art, such as by direct isolation of viral DNA from viral particles, by direct isolation of viral RNA transcribed as part of the SVII life cycle, by use of a hybridization method (i.e., identification of viral DNA in DNA libraries prepared from viral DNA, or virus- containing serum or plasma), by use of an amplification method (i.e., polymerase chain reaction of viral DNA, viral-DNA containing libraries, or DNA isolated from plasma or serum), or by direct synthesis.
- the polynucleotide sequence shown in FIG. 1 may be used to design probes or primers for use in hybridization and amplification methods and to select sequences for synthesis.
- Isolated genomic polynucleotides may be prepared by extraction of isolated viral particles. Isolated viral particles may be subjected to any DNA extraction technique known in the art, such as guanidinium HC1 extraction, optionally followed by further purification and/or concentration techniques such as agarose gel purification, phenol/chloroform extraction, or ethanol precipitation in the presence of salts. Preparation of DNA libraries is well known in the art. DNA isolated from viral particles or virus -containing plasma or serum may be cloned into a convenient library vector using techniques commonly used in the art.
- the library will be prepared using a lambda phage-based library vector, although cosmid and plasmid libraries are also commonly used.
- Phage-based libraries are plated by infection of 'lawns' of E. coli host cells, while cosmid and plasmid libraries are typically transformed into cells which are plated.
- DNA from the library is transferred to screening filters, and screening with a SVII polynucleotide probe.
- the probe is preferably modified such that hybridization can be detected, typically by the incorporation of a radioactive nucleotide (e.g. , P), although other modified probes (e.g.
- digoxigenin or biotin labeled may be detected through the use of a modified enzyme (e.g., alkaline phosphatase or luciferase) which binds the labeled probe and acts on a chromogenic or otherwise detectable substrate.
- a modified enzyme e.g., alkaline phosphatase or luciferase
- Clones hybridizing to the SVII polynucleotide probe are purified by one or more 'rounds' of purification (e.g., repeating the plating and screening process on progressively more purified clones), as is well known in the art.
- SVII DNA may be prepared by harvesting DNA from clones isolated in the screening procedure, and optionally further isolated from the library vector DNA by restriction endonuclease digestion.
- clone DNA isolated by screening may be used as a substrate for amplification of SVII virus DNA using polymerase chain reaction (PCR) methodology.
- PCR primers may be designed from SVII virus DNA or, more conveniently, may be designed to hybridize to DNA sequences in the library vector which flank the site at which the library DNA was inserted, as will be apparent to one of skill in the art.
- SVII virus polynucleotides may also be isolated by amplification from samples containing SVII DNA.
- Primers for amplification may be designed based on the sequence shown in FIG. 1, and are preferably designed so as to amplify SVII DNA, but not viral DNA from other viruses or genomic DNA from animals or prokaryotes. Additionally, as is well known in the art, the primer sequences are selected to minimize any intramolecular secondary structure, which substantially inhibits, and may even block, amplification. Protocols for polymerase chain reaction amplification are well known in the art, as are protocols for other amplification methods such as ligase chain reaction.
- the SVII DNA may be further purified by size selection (e.g., gel electrophoresis) or chemical extraction (e.g., phenol/chloroform extraction) and/or concentrated by ethanol precipitation in the presence of salts.
- size selection e.g., gel electrophoresis
- chemical extraction e.g., phenol/chloroform extraction
- SVII polynucleotides may also be chemically synthesized, although synthesized SVII polynucleotides are preferably less than about 50-60 nucleotides in length, as yields for polynucleotide synthesis drop as chain length increases.
- Methods for synthesis of polynucleotides are well known in the art, and generally involve the iterative addition of nucleotides (or modified nucleotides) to the growing end of the synthetic polynucleotide. A variety of different systems are available in the art, and the selection of the particular method and chemistry is left to the practitioner.
- SVII polynucleotides have a variety of uses, including detection of SVII virus (which is useful in diagnosis of SVII infection), production of SVII polypeptides, construction of SVII-based expression/transduction vectors, and as antisense oligonucleotides or for construction of antisense SVII vectors.
- Antisense SVII polynucleotides are SVII polynucleotides which are capable of selective hybridization to a segment of an mRNA molecules produced from an SVII genome.
- Antisense SVII polynucleotides may be any size SVII polynucleotide, but are preferably less than about 200 nucleotides length.
- Antisense SVII polynucleotides block expression of SVII proteins and/or SVII viral replication in SVII infected cells. Accordingly, SVII antisense polynucleotides may be used to treat SVII infections and/or ameliorate the symptoms of SVII infections, including reduction of SVII viremia.
- SVII antisense polynucleotides are chemically synthesized , they are preferably synthesized as modified oligonucleotides to increase resistance to nucleases.
- Modified oligonucleotides may be synthesized to include phosphoroamidites at the 5' and 3' termini (Dagle et al., 1990, Nucl Acids Res. 18:4751-4757), to incorporate the ethyl or methyl phosphonate analogs disclosed in U.S. Pat. No. 4,469,863, to incorporate phosphorothioate (Stein et al, 1988. Nucl. Acids Res.
- SVII antisense polynucleotides may be delivered to individuals infected with
- SVII antisense polynucleotides may be introduced into target cells via a vector, such as a viral vector.
- the vector comprises a promoter operable in a host cell, preferably a human host cell infected with SVII, operably linked to a polynucleotide sequence, transcription of which results in the production of an SVII antisense polynucleotide.
- Preferred viral vectors include, but are not limited to, the adeno-associated viral vectors known in the art.
- SVII antisense polynucleotides delivered by viral vector are administered intravenously, preferably into the portal vein.
- SVII proteins may comprise an entire ORF from a SVII virus, one or more fused proteins from a SVII virus, a single protein from a SVII virus, or fragments thereof. Also included are "mosaic proteins" which comprise two or more SVII protein fragments within the same protein.
- the SVII protein fragments in a mosaic protein may be from the same SVII protein or from different SVII proteins. Where the SVII protein fragments are from the same SVII protein, the amino acid sequence normally separating the fragments is substantially deleted or replaced with an unrelated "spacer" sequence.
- Another mosaic protein encompassed by the invention is a "superepitope" mosaic protein that comprises homologous versions of at least one epitope from at least two different SVII viruses. Superepitope mosaic proteins may be used, for example, in screening assays to generically detect SVII virus infection.
- SVII polypeptides may be prepared by any method known in the art, including purification from isolated viral particles, recombinant production and chemical synthesis. Due to the relative difficulty of isolating large amounts of viral particles from natural sources, recombinant production and/or chemical synthesis are preferred methods for production.
- a polynucleotide sequence encoding a protein of the invention is cloned into an "expression vector," which is introduced into a suitable host cell.
- the host cell is cultured under conditions appropriate for expression of the protein, and the recombinant protein is collected.
- the exact details of the expression construct will, as will be apparent to one of skill in the art, vary depending on the desired host cell and properties of the expression construct, although the expression construct will normally include a promoter/operator or promoter/enhancer operable in the host cell and a selectable marker allowing selection of cells containing the marker.
- the promoter/operator or promoter/enhancer is 'controllable' in that a change in culture conditions will lead to expression of the SVII protein (or SVII protein fusion protein).
- SVII peptides may be incorporated into "fusion proteins" for recombinant production.
- a fusion protein comprises a protein of interest
- the fusion partner may be at the amino terminal or carboxy terminal of the protein, although fusion proteins which incorporate the protein of interest as an 'insert' within the sequence of the coding region, are also contemplated. Fusion proteins comprising a SVII protein insert may be particularly useful as screening tools, for example, when incorporated into a "phage display" system (e.g., where the SVII protein sequence is inserted into a lambda phage coat protein).
- Useful fusion partners include proteins which allo ⁇ v for easy purification of the fusion protein (e.g., glutathione-S-transferase, oligo-histidine, and certain sequences derived from the myc oncogene), increase solubility of the fusion protein (such as E. coli DsbA, disclosed in U.S. Patent No. 5,629,172), or create a "linker" to bind the protein to a substrate (e.g., polyglycine with a terminal lysine could be used to link a SVII protein to substrate for use in an immunoassay).
- proteins which allo ⁇ v for easy purification of the fusion protein e.g., glutathione-S-transferase, oligo-histidine, and certain sequences derived from the myc oncogene
- increase solubility of the fusion protein such as E. coli DsbA, disclosed in U.S. Patent No. 5,629,172
- an expression construct is created by inserting a polynucleotide encoding a protein of the invention into an appropriate recombinant DNA expression vector using appropriate restriction endonucleases.
- the restriction endonuclease sites may be naturally occurring or synthetic sites that have been introduced by any method known in the art, such as site-directed mutagenesis, PCR or ligation of linker/adapters to the polynucleotide.
- the polynucleotide may be a synthetic sequence, designed to incorporate convenient restriction enzyme sites and/or optimize codon usage for the intended host cell.
- the particular endonucleases employed will be dictated by the restriction endonuclease cleavage pattern of the parent expression vector to be employed. The choice of restriction sites is made so as to properly orient the coding sequence with control sequences to achieve proper in-frame reading and expression of the protein.
- the polynucleotide may be inserted into any appropriate expression vector.
- Expression vectors may be found in a number of forms, including, but not limited to, plasmid, cosmid, yeast artificial chromosome (YAC), and viral.
- the expression vector will contain an autonomous replication site that is active at least in the organism in which the vector is propagated, and frequently also in the recombinant host cell.
- the expression vector will also typically include marker sequences which are capable of providing phenotypic selection in transformed cells, such as positive selection markers, such as an antibiotic resistance genes (e.g., bla, tet R , neo R or hyg R ) or genes which complement an auxotrophy (e.g., tip or DHFR) and/or negative selection markers such as herpes simplex virus 1 thymidine kinase.
- positive selection markers such as an antibiotic resistance genes (e.g., bla, tet R , neo R or hyg R ) or genes which complement an auxotrophy (e.g., tip or DHFR) and/or negative selection markers such as herpes simplex virus 1 thymidine kinase.
- the expression vector will also include necessary sequences for initiation and termination of transcription and translation (e.g., promoter, Shine-Dalgarno sequence, ribosome binding site, transcription termination site) and may optionally contain sequences which modulate transcription (e.g., SV40 enhancer or lac repressor), and may also contain sequences which direct processing, such as an intron or a polyadenylation site, as necessary.
- necessary sequences for initiation and termination of transcription and translation e.g., promoter, Shine-Dalgarno sequence, ribosome binding site, transcription termination site
- sequences which modulate transcription e.g., SV40 enhancer or lac repressor
- sequences which direct processing such as an intron or a polyadenylation site, as necessary.
- the polynucleotide of the invention is inserted into the expression vector in the proper orientation and relationship with the expression vector's transcriptional and translational control sequences to allow transcription from the promoter and translation from the ribosome binding site, both of which should be functional in the host cell in which the protein is to be expressed.
- the transcriptional control sequences are preferably inducible (i.e., can be modulated by altering the culture conditions, such as the lac operon for E. coli or the metallothionein promoter for mammalian cells).
- An example of such an expression vector is a plasmid described in Belagaje et al., U.S. Pat. No. 5,304,493.
- the gene encoding A-C-B proinsulin described in the reference can be removed from the plasmid pRB 182 with restriction enzymes Ndel and BamHI.
- the genes encoding the protein of the present invention can be inserted into the plasmid backbone on a Ndel/BamHI restriction fragment cassette.
- Microbial hosts are normally preferred for recombinant expression of the proteins of the invention, and any commonly used microbial host, including E. coli such as W3110 (prototrophic, ATCC NO. 27325), Bacillus subtilis, and other enterobacteriaceae such as Salmonella typhimurium or Serratia marcescans, and various pseudomonas species may be used.
- E. coli such as W3110 (prototrophic, ATCC NO. 27325), Bacillus subtilis, and other enterobacteriaceae such as Salmonella typhimurium or Serratia marcescans, and various pseudomonas species may be used.
- eukaryotic host cells including yeast such as Saccharomyces cerevisiae, Schizosaccharomyces pombe, as well as higher eukaryotes such as non-yeast fungal cells, plant cells, insect cells (e.g., Sf9), and mammalian cells (e.g., COS, CHO) may be used.
- yeast such as Saccharomyces cerevisiae, Schizosaccharomyces pombe
- higher eukaryotes such as non-yeast fungal cells, plant cells, insect cells (e.g., Sf9), and mammalian cells (e.g., COS, CHO)
- the completed expression construct is introduced into the recombinant host cell by any appropriate method known in the art, such as CaCl 2 transfection, Ca 2 PO transfection, viral transduction, lipid-mediated transfection, electroporation, ballistic transfection, and the like.
- the recombinant host cell is generally cultured under appropriate conditions to select for the presence of the expression construct (e.g., cultured in the presence of ampicillin for a bacterial host with an expression construct containing bla), or alternately may be selected for expression of the protein by any appropriate means (e.g., fluorescence activated cell sorting, FACS, using a SVII protein-specific antibody).
- FACS fluorescence activated cell sorting
- the recombinant host cells are cultured at production scale
- the promoter/enhancer in the expression vector is inducible, the expression of the protein is induced as appropriate for the particular construct (e.g., by adding an inducer, or by allowing a repressor to be depleted from the media) after the culture reaches an appropriate cell density, otherwise the cells are grown until they reach appropriate density for harvest.
- Harvesting of the recombinant proteins of the invention will depend on the exact nature of the recombinant host cells, the expression construct, and the polynucleotide encoding the protein of the invention, as will be apparent to one of skill in the art.
- the protein is normally recovered by removing media from the culture vessel, while expression constructs that result in intracellular accumulation of the protein generally require recovery and lysis of the cells to free the expressed protein.
- Proteins which are expressed in high-level bacterial expression systems characteristically aggregate in granules or inclusion bodies which contain high levels of the overexpressed protein.
- the protein aggregates are solubilized to provide further purification and isolation of the desired protein product, for example, using strongly denaturing solutions such as guanidinium-HCl, possibly in combination with a reducing agent such as dithiothreitol (DTT).
- the solubilized protein is recovered in its active form after a "refolding" reaction, in which generally involves reducing the concentration of the denaturant and adding oxidizing agent. Protocols which are considered generally applicable for the refolding of proteins are well known in the art, and are disclosed in, for example, U.S. Patents Nos.
- SVII proteins may also be conveniently produced using synthetic chemistry, a process well known in the art. Due to decreased yields at long peptide lengths, synthesis is a preferred method for production of peptides of about 15 amino acid residues or less.
- SVII polypeptides may be used in vaccines for prevention of SVII infection and/or treatment of SVII infection. Any SVII polypeptide or combination of SVII polypeptides maybe used in a SVII vaccine.
- SVII mosaic polypeptides comprising multiple epitopes from a single SVII protein, wherein the amino acids normally separating the epitopes are deleted are one preferred SVII protein for use in a vaccine formulation.
- Another preferred SVII protein for use in a vaccine is a superepitope protein which comprises homologous epitopes from multiple SVII viruses fused into a single protein.
- SVII vaccines are formulated according to methods known in the art. Preferably the vaccine is in a liquid formulation for parenteral administration.
- the vaccines may be formulated including pharmaceutical excipients known in the art such as physiologically and pharmaceutically acceptable salts, buffers, preservatives, bulking agents, osmolyte agents, and the like, which may be found in
- SVII protein-based vaccines may also be formulated with adjuvants.
- Adjuvants for use in SVII protein-based vaccines include chemical adjuvants such as aluminum hydroxide (especially aluminum hydroxide gels), potassium alum, protamine, aluminum phosphate and calcium phosphate, cytokine adjuvants including interleukin 1.beta, tumor necrosis factor alpha, and granulocyte-macrophage colony stimulating factor (GM-CSF), such as described in U.S. Patent No. 5,980,91 1, and oil in water emulsions such as Freund's complete and incomplete adjuvants.
- SVII vaccines are preferably delivered parenterally, more preferably by percutaneous administration.
- Prefered routes of administration include intramuscular and subcutaneous injection as well as percutaneous air-driven administration (e.g., needless injection).
- the vaccine may be given in a single dose or as multiple administrations. Where multiple administrations are given, they are preferably separated by at least one day, week, or month.
- Antibodies against SVII may be prepared using the isolated viral particles and/or SVII viral proteins provided by the instant invention. Isolated polyclonal antibodies as well as monoclonal antibodies may be made. Isolated polyclonal antibodies against SVII proteins are preferably prepared by injecting a "SVII immunogen" (e.g., isolated SVII viral particles, SVII protein(s), SVII oligopeptides linked to a carrier, or SVII fusion proteins) in an immuno genie form into an animal, preferably a mammal such as a rodent (e.g., a mouse, rat or rabbit), a goat, a cow or a horse.
- a "SVII immunogen” e.g., isolated SVII viral particles, SVII protein(s), SVII oligopeptides linked to a carrier, or SVII fusion proteins
- SVII immunogen is made as an oil/water emulsion complete adjuvant such as Freund's complete adjuvant, which contains a non-specific activator of the immune system to improve immune response to the injected immunogen. Later injections are typically made with incomplete adjuvant (e.g. , in an emulsion w/o a non-specific immune stimulator).
- the SVII immunogen can be introduced adsorbed to a solid substrate or as a simple solution.
- Serum is harvested and tested for the presence of specific antibody using any convenient assay, most typically a simple immunoassay such as an ELISA (enzyme-linked immunosorbent assay) using a SVII immunogen as the target and a species-specific anti-immunoglobin secondary antibody.
- a simple immunoassay such as an ELISA (enzyme-linked immunosorbent assay) using a SVII immunogen as the target and a species-specific anti-immunoglobin secondary antibody.
- Monoclonal antibodies of this invention can be prepared by a number of different techniques.
- the reader is referred generally to Harrow & Lane (1988), U.S. Patent Nos. 4.491,632, 4,472,500, and 4,444,887, and
- Immunocompetent means that the cell or particle has expressed or is capable of expressing an antibody specific for the antigen without further genetic rearrangement, and can be selected from a cell mixture by presentation of the antigen.
- Immunocompetent eukaryotic cells can be harvested from an immunized mammalian donor, or they can be harvested from an unimmunized donor and prestimulated in vitro by culturing in the presence of immunogen and immunostimulatory growth factors. Cells of the desired specificity can be selected by contacting with the immunogen under culture conditions that result in proliferation of specific clones but not non-specific clones.
- Immunocompetent phage may be constructed to express immunoglobulin variable region segments on their surface. See Marks et al., New Engl J. Med. 335:730, 1996; International Patent Applications Nos. 94/13804, 92/01047, 90/02809; and McGuinness et al., Nature Biotechnol 14:1149, 1996. Phage of the desired specificity may be selected, for example, by adherence to a SVII immunogen attached to a solid phase, and then amplified in E. coli.
- Antibody can be purified from serum, cell supernatants, lysates, or ascites fluid by a combination of traditional biochemical separation techniques, such as ammonium sulfate precipitation, ion exchange chromatography on a weak anion exchange resin such as DEAE, hydroxyapatite chromatography, and gel filtration chromatography.
- traditional biochemical separation techniques such as ammonium sulfate precipitation, ion exchange chromatography on a weak anion exchange resin such as DEAE, hydroxyapatite chromatography, and gel filtration chromatography.
- Specific affinity techniques such as affinity chromatography using a SVII immunogen as the affinity moiety may also be used, alone or in conjunction with traditional biochemical separation techniques to isolate antibodies of the invention.
- Antibodies obtained are preferably screened or purified not only for their ability to react with SVII viral proteins, but also for a low cross-reactivity with potential cross-reacting substances also present in samples of diagnostic interest. Unwanted activity can be adsorbed out of polyclonal antisera, if necessary, using the cross-reacting substance or an antigen preparation from serum from an individual negative for SVII infection.
- the epitope to which a particular antibody binds can be mapped by preparing fragments and testing the ability of the antibody to bind. For example, sequential peptides of 12 amino acids are prepared covering the entire sequence of the immunogen, and overlapping by 8 residues.
- the peptides can be prepared on a nylon membrane support by F-Moc chemistry, using a SPOTSTM kit from Genosys according to manufacturer's directions. Prepared membranes are then overlaid with the antibody, washed, and overlaid with anti-human IgG conjugated with either alkaline phosphatase or horseradish peroxidase. The test is developed by adding the appropriate substrate for the particular enzyme conjugate used. Positive staining indicates an antigen fragment recognized by the antibody. The fragment can then be used to obtain other antibodies recognizing the epitope of interest. Two antibodies recognizing the same epitope will compete for binding in a standard immunoassay. Antibodies of the invention may be used for the detection and/or identification of SVII virus, and may also be useful in isolation of viral particles and/or viral proteins.
- polynucleotides, proteins, and antibodies of the invention may be used in methods and kits for the detection of SVII viral infection and detection of SVII itself.
- Assays using the polynucleotides, proteins, and/or antibodies of the invention may be designed in a variety of formats, depending on the desired utility of the assay.
- Polynucleotides of the invention may be used for detection of SVII virus genomic DNA. Detection of SVII genomic DNA in blood samples indicates that the sample is contaminated with SVII virus and that the source of the sample is infected with SVII.
- a wide variety of different assays for detection of nucleotides are known, although all such assays generally require a hybridization step where a primer or probe is hybridized to DNA in the sample.
- oligomers of approximately eight nucleotides or more can be prepared, either by excision or synthetically, which hybridize with the SVII genome.
- the natural or derived probes for SVII polynucleotides are a length which allows the detection of unique viral sequences by hybridization. Generally, probes are a minimum of six to eight nucleotides in length, sequences of at least ten to twelve nucleotides are preferred, and those of at least about 20 nucleotides may be most preferred. Depending on the desired utility of the assay (e.g., detection of all SVII viruses vs. detection of a single SVII virus type), the probe may be based on a region of SVII genomic sequence which is conserved among SVII viruses or highly divergent among SVII viruses. These probes can be prepared using routine, standard methods including automated oligonucleotide synthetic methods.
- test sample to be analyzed such as blood or serum
- test sample to be analyzed such as blood or serum
- the nucleic acid sample is typically adsorbed to a solid support (e.g., nitrocellulose) for the assay (with or without preliminary size separation such as by gel electrophoresis), although solution phase format assays such as the assay described in U.S. Patent No. 4,868,105 may also be used.
- the probes may or may not be directly labeled or otherwise modified to allow later detection by binding of a label.
- Suitable labels and methods for attaching labels to probes are known in the art, and include but are not limited to radioactive labels incorporated by nick translation or kinasing, modifications which allow later binding of a label, such as biotinylation, as well as fluorescent and chemiluminescent labels which may be directly bound to the probe or bound via a modification of the probe.
- single-stranded sample nucleic acid is contacted with the probe under hybridization and wash conditions of suitable stringency, and resulting duplexes are detected.
- control of stringency is well known in the art, and depends on variables such as salt concentration, probe length, formamide concentration, temperature and the like.
- hybridization and washing is performed under stringent conditions.
- Detection of bound probe is performed according to requirements of the label/detection system employed in the assay. For example, where the probe is radioactively labeled, probe binding is detected by autoradiography.
- a label linked to a modification binding moiety e.g., streptavidin linked to a detectable enzyme such as alkaline phosphatase, green fluorescent protein or luciferase, or a fluorescent or other label bound to an anti- digoxigenin antibody.
- Detection of fluorescent probes is generally accomplished by fluorimeter, while luminescent labels may be detected using a luminometer or a photographic plate. Branched DNA technology and other methods which amplify signal from the assay may be employed (Urdea et al., 1989, Clin. Chem. 35(8):1571- 1575; U.S. Patent No. 5,849,481; ).
- Other assays employ probes as primers for amplification of SVII genomic
- SVII virus may also be detected using antibodies of the invention to detect the presence of viral proteins in a sample. Any of the wide variety of immunoassay formats known in the art may be used in conjunction with antibodies of the invention for detection of SVII virus or viral proteins.
- an immunoassay for detection of SVII virus or SVII protein in a sample detects a complex of SVII protein(s) with an antibody of the invention. At least one antibody of the invention is required, although preferred immunoassay formats require at least two antibodies of the invention.
- a detection antibody is contacted with the sample and the presence of the detection antibody is detected.
- the detection antibody may itself be detectable due to modification of the antibody with a dye or colored particles, it may be modified such that a detection reagent will bind to the detection antibody, or it may be modified with an enzyme which acts on a chromogenic substrate.
- the exact details of detection of the detection antibody will, of course, depend on the detection system utilized.
- Directly detectable detection antibodies may be detected by, for example, simple inspection, light microscopy or colorimetry (for antibodies modified with colored particles such as latex beads or colloidal metals), radiometry (for antibodies modified with a radioactive compound) or fiuorimetry or epifluorescence microscopy (for antibodies labeled with fluorescent dyes).
- Detection antibodies which have been modified to include an enzyme are typically detected by incubating the assay in a solution containing a substrate which becomes detectable upon processing by the enzyme (e.g. , substrates which change color or become fluorescent or luminescent after processing by the enzyme) and detecting any processed substrate using an appropriate method (e.g., colorimetry for chromogenic substrates, fiuorimetry for fluorescent substrates, and the like).
- detection antibodies may be modified to allow for "indirect” detection, where a second reagent which binds to the modified detection antibody allows detection of bound detection antibody.
- the second reagent is modified such that it is detectable (either directly as with a dye or colored particle, indirectly as with an enzyme and detectable substrate).
- RDA representation difference analysis
- Serum from a cryptogenic hepatitis patient designated HI 01 was used as the source of "tester" DNA.
- DNA was extracted by proteinase K digestion followed by phenol and chloroform extraction.
- DNA isolated from 100 ⁇ L HI 01 serum was digested to completion with 10 units of Sau3A I for three hours at 37 °C. The enzyme was inactivated by incubation at 65 °C for 20 minutes.
- Linkers R-Bgl-24 (5'-AGCACTCTCCAGCCTCTCACCGCA-3') and R-Bgl- 12 (5'-GATCTGCGGTGA-3') were ligated to the digested DNA by mixing the digested DNA with 1 nmol of each oligo in T4 DNA ligase buffer (with ATP, from New England Biolabs), denaturing the mixture by incubation for two minutes at 55 °C, annealing the linkers by gradually cooling the mixture to 10-15 °C over about an hour, then adding 800 units of T4 DNA ligase (New England Biolabs) and incubating overnight at 12-16 °C.
- T4 DNA ligase buffer with ATP, from New England Biolabs
- Tester amplicons were prepared by nested PCR reactions, since one round of PCR did not yield quantifiable amount of DNA.
- a portion of the ligation product was mixed with PCR buffer, dNTPs, and an additional 250 pmol of R-Bgl-24 oligo and overlaid with mineral oil.
- the R-Bgl-12 oligo was 'released' by incubating the mixture for three minutes at 72 °C. Overhangs were filled by adding 7.5 units of AMPLITAQ® Taq DNA polymerase (PE Biosystems) and incubating for a further five minutes at 72 °C.
- Tester amplicons were created by running the mixture through 20 cycles of one minute at 95 °C and three minutes at 72 °C followed by a final extension step at 72 °C for ten minutes.
- 10 ⁇ l of first round PCR product and linker R-Bgl-25 (5'-ACTCTCCAGCCTCTCACCGCAGATC-3') were used in the second round of PCR reaction under the same conditions as the first round for 15 cycles.
- the product was then extracted with phenol/chloroform and precipitated with sodium acetate and isopropanol. The precipitate was collected by centrifugation, air dried after removal of the supernatant, and resuspended in TE (tris-EDTA) buffer.
- the R- Bgl-24 linkers were removed by Sau3A I digestion essentially as above, followed by inactivation of the enzyme at 65 °C.
- the digestion product was precipitated using sodium acetate and ethanol in the presence of glycogen, collected by centrifugation, air dried following removal of the supernatant, and resuspended in TE.
- the product was then separated on a 1% agarose gel run in lx TAE, and the portion of the gel corresponding to 150-1500 nucleotides was cut out.
- Digested tester amplicons were purified from the gel using a QIAGEN® Qiaex II Gel Extraction kit according to the manufacturer's instructions.
- J-Bgl-24 and J-Bgl-12 linkers (5'-ACCGACGTCGACTATCCATGAACA-3' and 5'-GATCTGTTCATG-3 ⁇ respectively), essentially as described for the R-Bgl linkers.
- Driver amplicons were prepared from DNA extracted from serum pooled from 10 healthy blood donors essentially as described for tester amplicons, except that new linkers were not added after the second Sau3A I digestion.
- Driver and tester amplicons were mixed at a 100: 1 mass ratio, extracted with phenol/chloroform, and precipitated with sodium acetate and ethanol.
- the pellet was collected by centrifugation, air dried following removal of the supernatant, and resuspended in 4 ⁇ L of EE x 3 buffer (30 mM EPPS, pH 8.0, 3 mM EDTA).
- the mixture was overlaid with mineral oil hybridized by denaturing for five minutes at 98 °C, adding 1 ⁇ L of 5 M NaCl, incubating a further two minutes at 98 °C, then 20 hours at 65 °C.
- the tester/driver hybridization mix was amplified under conditions which selectively amplify only double stranded tester DNA. A portion of the hybridization mix was amplified for 10 cycles essentially as was done for amplification of the J-Bgl ligated tester DNA, except that the extension cycles were performed at 70 °C.
- the amplification product was collected, extracted with phenol/chloroform/isoamyl alcohol, then precipitated with sodium acetate and isopropanol. The precipitate was collected by centrifugation, air dried following removal of the supernatant, and resuspended in TE.
- Single stranded DNA was removed by digestion with mung bean nuclease (New England BioLabs) for 30 minutes at 30 °C, followed by heat inactivation of the enzyme at 98 °C for five minutes.
- the digestion product was the re-amplified for 15 cycles in the presence of additional J-Bgl-24 oligonucleotide.
- the product of the amplification was collected, extracted with phenol/chloroform/isoamyl alcohol, precipitated with sodium acetate and isopropanol, collected by centrifugation, washed with 70% ethanol, air dried following removal of the supernatant, and resuspended in TE to form the First Difference Product (DPI).
- the Second Difference Product (DP2) was created by digesting DPI with Sau3 A I and substituting N-Bgl linkers (N-Bgl- 12 and N-Bgl-24,
- the Third Difference Product was created by digesting DP2 with Sau3A I and substituting J-Bgl linkers for the N-Bgl linkers, followed by followed by hybridization with driver amplicons at a 4 x 10 5 :1 driver :tester mass ratio, and amplification/digestion amplification as for DPI . After three rounds subtractive hybridization and selective amplification, distinct bands were seen after gel electrophoresis, as compared to the 'smear' patterns of the original tester amplicons. DNA was isolated from each band using a QIAGEN® Gel Extraction Kit (Cat. No. 28704) according to the manufacturer's instructions, then ligated into TA plasmid 2.1 (InVitrogen Cat. K2000-01).
- ORF 1 The amino acid sequence of ORF 1 is also shown in FIG. 1.
- the non-human origin of clone 33 was confirmed by PCR. No amplification product was detected after amplification of human genomic DNA using PCR primers specific for clone 33. Upon confirmation of the non-human origin of clone 33, it was redesignated Sentinel Virus II, or SVII. The presence of SVII was confirmed in patient H 101 ' s serum at two time points corresponding to peak ALT levels, using PCR primers specific for SVII.
- SVII positive serum was fractionated by density gradient ultracentrifugation to determine the buoyant density of SVII viral particles.
- the first round used primer pair 33.1/33.2 (5'-GGATTGACGACGACGACGAC-3' and 5'-TGTCAAATACCCGCTCAGGA-3', respectively), and the second round used primer pair 33.3/33.4 (5'-GACGACGACGACGACATTG-3' and 5'-CAAATACCCGCTCAGGAAGG-3', respectively).
- SVII buoyant density was also measured in CsCl gradient.
- More than 700 serum samples were assayed by PCR for presence of SVII.
- the samples were divided into: (a) "super normal” blood donors (normal blood values, no hepatitis virus markers, and not implicated in transfusion-related events for > 5 blood donations); (b) "normal” blood donors (meeting blood donation criteria); (c) "disqualified” blood donors (healthy individuals not eligible for blood donation under current rules); and (d) "hepatitis” patients, separated into acute hepatitis, chronic HBV, chronic HCV, cryptogenic (nonA-E), and superinfected hepatits (HBV and
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA02010880A MXPA02010880A (en) | 2000-05-05 | 2001-05-04 | Sentinel virus ii. |
EP01943319A EP1282692A2 (en) | 2000-05-05 | 2001-05-04 | Sentinel virus ii |
AU65924/01A AU769292B2 (en) | 2000-05-05 | 2001-05-04 | Sentinel virus II |
BR0110576-0A BR0110576A (en) | 2000-05-05 | 2001-05-04 | Sentinel Virus II |
CA002406644A CA2406644A1 (en) | 2000-05-05 | 2001-05-04 | Sentinel virus ii |
JP2001582369A JP2003532403A (en) | 2000-05-05 | 2001-05-04 | Sentinel virus II |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20227100P | 2000-05-05 | 2000-05-05 | |
US60/202,271 | 2000-05-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001085770A2 true WO2001085770A2 (en) | 2001-11-15 |
WO2001085770A3 WO2001085770A3 (en) | 2002-03-28 |
Family
ID=22749170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/005029 WO2001085770A2 (en) | 2000-05-05 | 2001-05-04 | Sentinel virus ii |
Country Status (11)
Country | Link |
---|---|
US (1) | US20030165540A1 (en) |
EP (1) | EP1282692A2 (en) |
JP (1) | JP2003532403A (en) |
KR (1) | KR20030032947A (en) |
CN (1) | CN1440456A (en) |
AU (1) | AU769292B2 (en) |
BR (1) | BR0110576A (en) |
CA (1) | CA2406644A1 (en) |
MX (1) | MXPA02010880A (en) |
PL (1) | PL365842A1 (en) |
WO (1) | WO2001085770A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7935710B2 (en) | 2002-05-13 | 2011-05-03 | Tibotec Pharmaceuticals Ltd. | Microbicidal pyrimidine or triazine for preventing sexual HIV transmission |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058638A2 (en) * | 1998-05-13 | 1999-11-18 | Innogenetics N.V. | Sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections |
-
2001
- 2001-05-04 US US09/849,729 patent/US20030165540A1/en not_active Abandoned
- 2001-05-04 WO PCT/EP2001/005029 patent/WO2001085770A2/en not_active Application Discontinuation
- 2001-05-04 BR BR0110576-0A patent/BR0110576A/en not_active IP Right Cessation
- 2001-05-04 CN CN01812236A patent/CN1440456A/en active Pending
- 2001-05-04 AU AU65924/01A patent/AU769292B2/en not_active Ceased
- 2001-05-04 KR KR1020027014822A patent/KR20030032947A/en not_active Application Discontinuation
- 2001-05-04 EP EP01943319A patent/EP1282692A2/en not_active Withdrawn
- 2001-05-04 JP JP2001582369A patent/JP2003532403A/en active Pending
- 2001-05-04 PL PL01365842A patent/PL365842A1/en unknown
- 2001-05-04 MX MXPA02010880A patent/MXPA02010880A/en unknown
- 2001-05-04 CA CA002406644A patent/CA2406644A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058638A2 (en) * | 1998-05-13 | 1999-11-18 | Innogenetics N.V. | Sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections |
Non-Patent Citations (1)
Title |
---|
MENON K, ZEIN N: "What do we know about non-A-to-E viral hepatits?" CURRENT GASTROENTEROLOGY REPORT, vol. 2, no. 1, - February 2000 (2000-02) pages 33-39, XP001041489 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7935710B2 (en) | 2002-05-13 | 2011-05-03 | Tibotec Pharmaceuticals Ltd. | Microbicidal pyrimidine or triazine for preventing sexual HIV transmission |
Also Published As
Publication number | Publication date |
---|---|
EP1282692A2 (en) | 2003-02-12 |
PL365842A1 (en) | 2005-01-10 |
BR0110576A (en) | 2003-04-01 |
AU6592401A (en) | 2001-11-20 |
US20030165540A1 (en) | 2003-09-04 |
CA2406644A1 (en) | 2001-11-15 |
WO2001085770A3 (en) | 2002-03-28 |
CN1440456A (en) | 2003-09-03 |
MXPA02010880A (en) | 2003-03-27 |
JP2003532403A (en) | 2003-11-05 |
AU769292B2 (en) | 2004-01-22 |
KR20030032947A (en) | 2003-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0013828B1 (en) | Recombinant DNA, hosts transformed with it and processes for the preparation of polypeptides | |
JP2543751B2 (en) | Method for producing antigenic protein | |
BE1005485A5 (en) | Viral agent. | |
EP0423239A1 (en) | Post-transfusion, non-a, non-b hepatitis virus and antigens | |
US5218099A (en) | Post-transfusion, non-A, non-B hepatitis virus polynucleotides | |
US20100286070A1 (en) | Affinity tag | |
JPH08504096A (en) | Recombinant proteins of hepatitis E Pakistan strains and their use in diagnostics and vaccines | |
JPH04506608A (en) | Intestinally transmitted non-A/non-B hepatitis viral substances and their characteristic epitopes | |
EP0182442B1 (en) | Recombinant dna molecules and their method of production | |
US20010034018A1 (en) | Hepatitis virus sentinel virus I (SVI) | |
AU769292B2 (en) | Sentinel virus II | |
US6268122B1 (en) | Recombinant DNA molecules and their method of production | |
JPH06507552A (en) | DNA sequences and encoded polypeptides useful in the diagnosis of hepatitis diseases | |
CN1318646A (en) | Coded salmonella typhi specific and antigenic outer membrane protein DNA sequence | |
US20050037336A1 (en) | Hxhv virus, nucleic material, peptide material and uses | |
JP3831035B2 (en) | Hepatitis C virus sensitive recombinant hepatocytes and use thereof | |
WO1992018532A1 (en) | Rna, dna and virus antigen protein of non-a non-b hepatitis virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001943319 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 65924/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2406644 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-3631 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/010880 Country of ref document: MX Ref document number: 1020027014822 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018122361 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001943319 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027014822 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-3631 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 65924/01 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001943319 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020027014822 Country of ref document: KR |